The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Phase I Study of Anti–Epidermal Growth Factor Receptor Antibody Cetuximab in Combination With Radiation Therapy in Patients With Advanced Head and Neck Cancer
Abstract
PURPOSE: To evaluate the safety, pharmacokinetics, and efficacy of a chimeric anti–epidermal growth factor receptor monoclonal antibody, cetuximab, in combination with radiation therapy (RT) in patients with advanced squamous cell carcinoma of the head and neck. PATIENTS AND METHODS: We treated 16 patients in five successive treatment schedules. A standard dose escalation procedure was used; three patients entered onto the study at each dose level of cetuximab received conventional RT (70 Gy, 2 Gy/d), and the final three patients received hyperfractionated RT (76.8 Gy, 1.2 Gy bid). Cetuximab was delivered as a loading dose of 100 to 500 mg/m 2, followed by weekly infusions of 100 to 250 mg/m 2 for 7 to 8 weeks. Circulating levels of cetuximab during therapy were determined using a biomolecular interaction analysis core instrument. Human antichimeric antibody response was evaluated with a double-antigen radiometric assay. The recommended phase II/III dose was defined as the optimal cetuximab dose level based on the pharmacologic parameters and adverse events. RESULTS: The most commonly reported adverse events were fever, asthenia, transaminase elevation, nausea, and skin toxicities (grade 1 to 2 in most patients). Skin toxicity outside of the RT field was not strictly dose-dependent; however, grade 2 or higher events were observed in patients treated with higher dose regimens. There was one grade 4 allergic reaction. Most acute adverse effects were associated with RT (xerostomia, mucositis, and local skin toxicity). No antibodies against cetuximab were detected. All patients achieved an objective response (13 complete and two partial remissions). CONCLUSION: Cetuximab can be safely administered with RT. The recommended dose for phase II/III studies is a loading dose of 400 to 500 mg/m 2 and a maintenance weekly dose of 250 mg/m 2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Pignon, J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)90011-0 · Cited by 2,543
Al-Sarraf, M., LeBlanc, M., Giri, P. G., Fu, K. K., Cooper, J., Vuong, T., Forastiere, A. A., Adams, G., Sakr, W. A., Schuller, D. E., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.4.1310 · Cited by 2,222
The hazard of accelerated tumor clonogen repopulation during radiotherapy
Withers, H. R., Taylor, J. M. G., & Maciejewski, B. (1988) · Acta Oncologica · doi:10.3109/02841868809090333 · Cited by 1,601
Fu, K. K., Pajak, T. F., Trotti, A., Jones, C. U., Spencer, S. A., Phillips, T. L., Garden, A. S., Ridge, J. A., Cooper, J. S., & Ang, K. K. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)00663-5 · Cited by 1,357
Self-citationBrizel, D. M., Albers, M. E., Fisher, S. R., Scher, R. L., Richtsmeier, W. J., Hars, V., George, S. L., Huang, A. T., & Prosnitz, L. R. (1998) · New England Journal of Medicine · doi:10.1056/nejm199806183382503 · Cited by 1,127
Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival
Grandis, J. R., Melhem, M. F., Gooding, W. E., Day, R., Holst, V. A., Wagener, M. M., Drenning, S. D., & Tweardy, D. J. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.11.824 · Cited by 1,113
Goldstein, N. I., Prewett, M. C., Zuklys, K., Rockwell, P., & Mendelsohn, J. M. (1995) · PubMed · Cited by 910
Gatenby, R. A., Kessler, H. B., Rosenblum, J. S., Coia, L. R., Moldofsky, P. J., Hartz, W. H., & Broder, G. J. (1988) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(88)90002-8 · Cited by 798
Kawamoto, T., Sato, J. D., Le, A., Polikoff, J., Sato, G. H., & Mendelsohn, J. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.5.1337 · Cited by 791
Baselga, J., Pfister, D., Cooper, M. R., Cohen, R., Burtness, B., Bos, M., D’Andrea, G., Seidman, A., Norton, L., Gunnett, K., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.4.904 · Cited by 741
Self-citationIn vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody.
Milas, L., Mason, K. A., Hunter, N. R., Petersen, S. H., Yamakawa, M., Ang, K. K., Mendelsohn, J. M., & Fan, Z. (2000) · PubMed · Cited by 537
Gill, G. N., Kawamoto, T., Cochet, C., Le, A., Sato, J. D., Masui, H., McLeod, C., & Mendelsohn, J. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42857-2 · Cited by 455
Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer.
Dassonville, O., Formento, J. L., Francoual, M., Ramaioli, A., Santini, J., Schneider, M., Demard, F., & Milano, G. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.10.1873 · Cited by 415
Schmidt-Ullrich, R. K., Mikkelsen, R. B., Dent, P., Todd, D. G., Valerie, K., Kavanagh, B. D., Contessa, J. N., Rorrer, W. K., & Chen, P. B. (1997) · Oncogene · doi:10.1038/sj.onc.1201275 · Cited by 412
Grandis, J. R., Melhem, M. F., Barnes, E. L., & Tweardy, D. J. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960915)78:6<1284::aid-cncr17>3.0.co;2-x · Cited by 369
An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer
Munro, A. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.17 · Cited by 348
Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy.
Mendelsohn, J. M. (1997) · PubMed · Cited by 344
Human Immune Respone to Monoclonal Antibodies
Khazaeli, M. B., Conry, R. M., & LoBuglio, A. F. (1994) · Journal of Immunotherapy · doi:10.1097/00002371-199401000-00006 · Cited by 301
Self-citationFan, Z., Lu, Y., Wu, X., & Mendelsohn, J. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47026-3 · Cited by 283
Santini, J., Formento, J., Francoual, M., Milano, G., Schneider, M., Dassonville, O., & Demard, F. (1991) · Head & Neck · doi:10.1002/hed.2880130209 · Cited by 254
Jeremic, B., Shibamoto, Y., Stanisavljevic, B., Milojevic, L., Milicic, B., & Nikolic, N. (1997) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(97)00048-0 · Cited by 252
Prewett, M., Scher, H. I., Rockwell, P., Rockwell, R. F., Giorgio, N. A., Mendelsohn, J., & Goldstein, N. I. (1996) · Journal of Immunotherapy · doi:10.1097/00002371-199611000-00006 · Cited by 244
ANG, K. K., Peters, L. J., Weber, R. S., Maor, M. H., Morrison, W. H., Wendt, C. D., & Brown, B. W. (1990) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(90)90341-g · Cited by 232
Epidermal Growth Factor Receptor Family and Chemosensitization
Mendelsohn, J., & Fan, Z. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.5.341 · Cited by 171
Saleh, M. N., Raisch, K. P., Stackhouse, M. A., Grizzle, W. E., Bonner, J. A., Mayo, M. S., Kim, H., Meredith, R. F., Wheeler, R. H., & Buchsbaum, D. J. (1999) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.1999.14.451 · Cited by 164
Self-citationGrandis, J. R., Tweardy, D. J., & Melhem, M. F. (1998) · PubMed · Cited by 120
Bonner, J. A., Maihle, N. J., Folven, B. R., Christianson, T. J. H., & spain, K. (1994) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(94)90269-0 · Cited by 106
Self-citationPerez-Soler, R., Donato, N. J., Shin, D. M., Rosenblum, M. G., Zhang, H. Z., Tornos, C. S., Brewer, H., Chan, J. C., Lee, J. S., & Hong, W. K. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.4.730 · Cited by 70
Peter, R. U., Beetz, A., Ried, C., Michel, G., Beuningen, D. V., Ruzicka, T., & Michel, G. (1993) · Radiation Research · doi:10.2307/3578641 · Cited by 61
Characterization of radiation sensitivity of human squamous carcinoma A431 cells
Ng, C., Keng, P. C., & Sutherland, R. (1987) · British Journal of Cancer · doi:10.1038/bjc.1987.193 · Cited by 20
Khazaeli, M. B. (1989) · Hybridoma · doi:10.1089/hyb.1989.8.231 · Cited by 16
Self-citation
Cited by
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,115
Self-citationTargeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256
PI3K/Akt signalling pathway and cancer
Vara, J. Á. F., Casado, E., de Castro, J., Cejas, P., Belda-Iniesta, C., & González-Barón, M. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2003.07.007 · Cited by 2,443
Bonner, J. A., Harari, P. M., Giralt, J., Cohen, R. B., Jones, C. U., Sur, R. K., Raben, D., Baselga, J., Spencer, S. A., Zhu, J., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70311-0 · Cited by 1,978
Self-citationStatus of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer
Mendelsohn, J., & Baselga, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.504 · Cited by 1,255
Metadata
- Authors
- Robert, F., Ezekiel, M. P., Spencer, S. A., Meredith, R. F., Bonner, J. A., Khazaeli, M. B., Saleh, M. N., Carey, D., LoBuglio, A. F., Wheeler, R. H., Cooper, M. R., & Waksal, H. W.
- Venue
- Journal of Clinical Oncology
- Published
- 2001-07-01
- Volume
- 19
- Issue
- 13
- Pages
- 3234-3243
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2167531081
- Cited by
- 474
- References
- 32
- FWCI
- 43.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.